PFE logo

Pfizer Inc. Stock Price

NYSE:PFE Community·US$157.2b Market Cap
  • 5 Narratives written by author
  • 1 Comments on narratives written by author
  • 1025 Fair Values set on narratives written by author

PFE Share Price Performance

US$27.65
1.40 (5.33%)
US$29.08
Fair Value
US$27.65
1.40 (5.33%)
4.9% undervalued intrinsic discount
US$29.08
Fair Value
Price US$27.65
AnalystConsensusTarget US$29.08
AnalystHighTarget US$34.98
Valrodmon US$28.00

PFE Community Narratives

AnalystConsensusTarget·
Fair Value US$29.08 4.9% undervalued intrinsic discount

Expanding Oncology Pipelines And Emerging Markets Will Unlock Future Success

6users have liked this narrative
1users have commented on this narrative
480users have followed this narrative
AnalystHighTarget·
Fair Value US$34.98 21.0% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Unlock New Opportunities

3users have liked this narrative
0users have commented on this narrative
48users have followed this narrative
Valrodmon·
Fair Value US$28 1.3% undervalued intrinsic discount

Pfizer is about resilience and dividend yield

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
PFE logo
Pfizer

Pfizer is about resilience and dividend yield

O Futuro da Pfizer (PFE): Uma Narrativa de Transição e Resiliência No final de 2025, a Pfizer Inc. (PFE) encontra-se em um momento pivotal de sua história.Read more

View narrative
361
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
US$28
1.3% undervalued intrinsic discount
Valrodmon's Fair Value
Revenue
9.77% p.a.
Profit Margin
15.6%
Future PE
14.5x
Price in 2030
US$39.19
US$30.62
9.7% undervalued intrinsic discount
Francisco's Fair Value
Revenue
11.82% p.a.
Profit Margin
12.6%
Future PE
18.55x
Price in 2028
US$36.69
US$34.98
21.0% undervalued intrinsic discount
Revenue
-1.27% p.a.
Profit Margin
19.2%
Future PE
21.06x
Price in 2029
US$42.82
US$23
20.2% overvalued intrinsic discount
Revenue
-6.76% p.a.
Profit Margin
17.63%
Future PE
18.01x
Price in 2029
US$28.41

Trending Discussion

Updated Narratives

PFE logo

Pfizer is about resilience and dividend yield

Fair Value: US$28 1.3% undervalued intrinsic discount
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PFE logo

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Fair Value: US$30.62 9.7% undervalued intrinsic discount
31 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PFE logo

PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating

Fair Value: US$34.98 21.0% undervalued intrinsic discount
48 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Average dividend payer with slight risk.

4 Risks
1 Reward

Pfizer Inc. Key Details

US$62.6b

Revenue

US$15.1b

Cost of Revenue

US$47.4b

Gross Profit

US$39.7b

Other Expenses

US$7.7b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
1.36
75.81%
12.38%
74.9%
View Full Analysis

About PFE

Founded
1849
Employees
75000
CEO
Albert Bourla
WebsiteView website
www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Recent PFE News & Updates

Recent updates

No updates